Only a small fraction of patients with HCC benefit from immune checkpoint inhibitor (ICI) therapy. Recently published studies suggest that HCC in patients with NASH does not respond the ICI therapy. I
Additional file 5. Supplementary information for annotation of each UMAP cluster, including elevated tissues generated from the hypergeometric test (FDR < 0.001 in sheet 3; Cluster tissue hypergeom),
